PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35513832-1	2022	BACKGROUND: Anlotinib, an oral small molecule tyrosine kinase inhibitor targeting VEGFR 1/2/3, FGFR 1-4, PDGFR a/beta, and c-kit, had demonstrated prolonged progression-free survival (PFS) in refractory metastatic colorectal cancer (mCRC).	anlotinib	12-21	platelet derived growth factor receptor alpha	Homo sapiens	105-117	
34812950-0	2021	Targeted therapy with anlotinib for a H3K27M mutation diffuse middle glioma patient with PDGFR-alpha mutation: a case report.	anlotinib	22-31	platelet derived growth factor receptor alpha	Homo sapiens	89-100	
34434895-14	2021	The results of immunohistochemistry showed that XHW combined with anlotinib reduced the expression of PDGFRA in tumors.	anlotinib	66-75	platelet derived growth factor receptor alpha	Homo sapiens	102-108	
32587778-10	2020	Upregulation of CD105 was abrogated by anlotinib, which targets multiple receptor tyrosine kinases including VEGFR2/3, FGFR1-4, PDGFRalpha/beta, C-Kit, and RET.	anlotinib	39-48	platelet derived growth factor receptor alpha	Homo sapiens	128-143	
33740528-7	2021	Western blot analysis demonstrated that anlotinib significantly inhibited the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2) and platelet-derived growth factor receptor beta (PDGFR-beta), as well as their downstream signaling pathways stimulated by VEGF or PDGF-BB, in a concentration-dependent manner in ECs and pericytes.	anlotinib	40-49	platelet derived growth factor receptor alpha	Homo sapiens	202-212	
32949176-6	2021	Anlotinib is a multitarget tyrosine kinase inhibitor that was originally designed to inhibit VEGFR2/3, FGFR1-4, PDGFRalpha/beta, and c-Kit.	anlotinib	0-9	platelet derived growth factor receptor alpha	Homo sapiens	112-127	
35278141-0	2022	Correction to: Targeted therapy with anlotinib for a H3K27M-mutant diffuse midline glioma patient with PDGFR-alpha mutation: a case report.	anlotinib	37-46	platelet derived growth factor receptor alpha	Homo sapiens	103-114	
32724339-2	2020	Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1-4, platelet-derived growth factor receptor alpha and beta, c-Kit and Ret.	anlotinib	0-9	platelet derived growth factor receptor alpha	Homo sapiens	163-208	
32724339-2	2020	Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1-4, platelet-derived growth factor receptor alpha and beta, c-Kit and Ret.	anlotinib	11-17	platelet derived growth factor receptor alpha	Homo sapiens	163-208	
27716285-1	2016	BACKGROUND: Anlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR alpha/beta, c-Kit, and Ret.	anlotinib	12-21	platelet derived growth factor receptor alpha	Homo sapiens	129-140	
32266457-1	2020	PURPOSE: Anlotinib is a novel oral multi-targeted receptor tyrosine kinase inhibitor, which selectively inhibits VEGFR2/3, FGFR1-4, PDGFR alpha/beta, c-kit, and Ret.	anlotinib	9-18	platelet derived growth factor receptor alpha	Homo sapiens	132-148